Alltrna is a clinical-stage biotechnology company unlocking tRNA biology to treat disease. With the world’s first and most advanced tRNA therapeutic design platform, Alltrna is creating programmed medicines to treat genetic diseases with shared underlying mutations, rather than one gene or condition at a time. The company is advancing a pipeline of engineered tRNA therapeutics, with initial programs focused on diseases where a single tRNA therapeutic could potentially address multiple conditions driven by the same genetic variant. This pipeline is supported by an integrated platform that brings together tRNA biology, oligonucleotide engineering, delivery, manufacturing, and AI/ML-enabled design and optimization. Founded in 2018 by Flagship Labs, the innovation foundry of Flagship Pioneering, Alltrna is translating tRNA biology into a scalable, mutation-defined approach to genetic medicine.
| Website | http://www.alltrna.com |
| Revenue | $13.7 million |
| Employees | 45 (45 on RocketReach) |
| Founded | 2018 |
| Industry | Biotechnology Research |
| Keywords | Biotech Platform, Protein Synthesis, Rna Modification, Rna Research, Therapeutic Platform, Rna Therapeutics, Gene Therapy, Disease Treatment, Drug Discovery, Biotechnology, Pharmaceutical, Precision Medicine, Messenger Rna, Molecular Biology, Genetic Engineering, Epigenetics |
| Competitors | Biogen, Moderna Therapeutics, Intellia Therapeutics, Inc., Avidity Biosciences, Inc., Arcturus Therapeutics, CureVac, Sangamo Therapeutics, Inc., Zymergen, Inc., Molecular Partners, Aptamer Group +47 more (view full list) |
Looking for a particular Alltrna employee's phone or email?
The Alltrna annual revenue was $13.7 million in 2026.
Nerissa Kreher is the Chief Medical Officer of Alltrna.
45 people are employed at Alltrna.
Alltrna is based in Cambridge, Massachusetts.